Vertex Pharmaceuticals Inc / MA (VRTX) financials

Vertex Pharmaceuticals Inc / MA (VRTX) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Vertex Pharmaceuticals Inc / MA reported revenue of $12.00B, up 8.9% year over year, net income of $3.95B, diluted EPS of $15.32 and free cash flow of $3.19B.

Revenue (fiscal 2025)

$12.00B

Revenue growth (fiscal 2025)

8.9%

Net income (fiscal 2025)

$3.95B

Diluted EPS (fiscal 2025)

$15.32

Free cash flow (fiscal 2025)

$3.19B

Vertex Pharmaceuticals Inc / MA files with the U.S. Securities and Exchange Commission under CIK 0000875320, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.